Gothenburg, March 16 2016

PExAs product CE marked

PExA AB ("PExA") announces that the company's product PExA 2.0 is now CE marked. The CE marking means that it can be sold freely to the research market throughout the European Economic Area.

CEO Erik Ekbo comments

– That we now have the product CE marked is extremely important for us. One of our main strategies in the continued development work is to further broaden and deepen the cooperation with internationally leading lung research institutions. We can now begin the next phase in our efforts to establish the product in the research market with more focus on marketing and sales.

Planned market launch in high-priority countries in Europe during the second quarter of 2016

PExA now continues the work ahead for the launch of PExA 2.0 which, according to the company's plan, will begin during the second quarter of 2016. Initially, PExA plans to sell and distribute instruments and the method to lung research institutions in academia and healthcare as well as to pharmaceutical companies, all of whom are currently looking for biomarkers. Globally, PExA has identified about 1,500 such research groups as primary targets. More and more researchers focus their work towards finding these biomarkers and there is today, according to the Board, no alternative that is just as reliable, reproducible and non-invasive as PExA 2.0 on the market.

Potential biomarkers for common diseases

The company's patented method is like a non-invasive blood test for the small airways and can be used to detect lung diseases at an early stage. The method enables the collection of microscopic trace elements from the exhaled breath in researchers' effort to find biomarkers for common diseases affecting the airways. Among which asthma and chronic obstructive pulmonary disease (COPD) are included. Worldwide, lung diseases are according to the World Health Organization (WHO), the third leading cause of death, with more than five million deaths annually.

CE marking

PExA 2.0 is CE marked in accordance with the EU Directive for low voltage (2006/95/EC) as well as electromagnetic compatibility (2004/108/EC). The CE mark means that PExA 2.0 can be sold freely to the research market throughout the European Economic Area, EEA (EU, Norway, Iceland and Liechtenstein). It is also an assurance that the product meets the applicable requirements of the EU directive.

Well documented method

PExAs unique collection method has been developed since the 2000s by researchers at the University of Gothenburg and the method is well documented in over 15 scientific articles and three doctoral theses. More information on these can be found on the company's website, www.pexa.se.

For more information about PExA, please contact:
Erik Ekbo, CEO
Phone: +46 723-92 30 30
Email: erik@pexa.se

PExA AB *(556956-9246) develops and markets a research instrument with associated products and services to lung researchers for simple and non-invasive sampling, in order to study respiratory diseases such as asthma and chronic obstructive pulmonary disease, COPD. Sampling with PExA can be used to detect lung diseases at an early stage. The sample can be likened to a "blood test for the small airways". The aim is to facilitate the development of reliable and more individualised diagnosis, monitoring and treatment of respiratory diseases. The original idea and research behind the method comes from the unit for Occupational and Environmental Medicine at the Sahlgrenska Academy at Gothenburg University. Commercial operations started in 2010 with the support of GU Ventures incubator, and the company is founded by inventors, key persons, business angels and GU Ventures. The company's B shares are listed on AktieTorget.*